Results

Total Results: 2,181 records

Showing results for "harms".

101. Decisional Dilemmas in Discontinuing Prolonged Disease-Modifying Treatment for Multiple Sclerosis | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/multiple-sclerosis/research
     December 01, 2019 - disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long-term benefits and harms … information: 16 of these contained complete information to allow full analysis of long-term benefits and harms … Limited low-strength evidence suggests that long-term harms do not differ from short-term harms.

102. CER 218 Evidence Summary: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-fracture-prevention-evidence-summary.pdf
     April 01, 2019 - • Long-term oral hormone therapies reduce hip and clinical fractures but increase multiple serious harms … of long-term denosumab, risedronate, ibandronate, teriparatide, and abaloparatide on fractures and harms … Evidence on efficacy of long-term (>3 years) osteoporosis drug treatment (continued) Harms Due to … Fifth, reporting on harms was sparse and inconsistent between studies, limiting confidence around harms … Future studies should systematically collect, analyze and report harms data.

103. Infantile-Hemangioma Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/infantile-hemangioma_executive.pdf
     January 01, 2016 - We considered 14 of these as good quality for harms reporting, 3 as fair quality for harms reporting … The studies did not address harms. KQ2. … any harms. … Surgical harms included wound dehiscence. … Topical timolol RCT: 1 (41) Cohort studies: 4 (287) Case series: 1 (25) Lack of harms Low No harms

104. Acute Treatments for Episodic Migraine | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/migraine-treatments/protocol
     March 01, 2020 - harms, infections, cardiovascular events, cognitive harms, and psychological harms (e.g., depression … including gastrointestinal-related harms, cardiovascular-related harms, kidney-related harms, falls, … fractures, motor vehicle accidents, endocrinological harms, infections, cognitive harms, and psychological … harms (e.g., depression)? … Misuse, opioid use disorder, overdose and other harms KQ 2.

105. Blood-based Tests for Multiple Cancer Screening: A Systematic Review | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/cell-free-dna/draft-report
     January 01, 2025 - The objective of this systematic review was to assess the accuracy, benefits, and harms of screening … Eligible designs included controlled studies for outcomes of effectiveness and harms of screening (e.g … No controlled studies evaluated the benefits or harms of screening with MCSTs. … The evidence was insufficient to assess the harms of diagnostic evaluation after a positive test: one … We identified no studies that reported the benefits or harms of screening with MCSTs, though some ongoing

106. Patient Safety | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/patient-safety
     April 02, 2025 - Rapid Evidence Product April 2, 2025 Making Healthcare Safer IV: Programs for Responding to Harms … Research Protocol August 5, 2024 Making Healthcare Safer IV: Programs for Responding to Harms … Organisms Rapid Evidence Product February 1, 2024 Deprescribing To Reduce Medication Harms … Service Rapid Evidence Product September 14, 2023 Making Healthcare Safer IV: Potential Harms … Research Protocol September 5, 2023 Making Healthcare Safer IV: Deprescribing to Reduce Medication Harms

107. AHRQ Evidence-Based Practice Center (EPC) Program Research Gaps Summary: Pain Management (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gaps-pain-management.pdf
     January 01, 2023 - Congress, was to evaluate the evidence on benefits and harms of cannabinoids and similar plant-based … • Longitudinal studies on opioids to evaluate longer-term outcomes, including associated harms … • Longitudinal outcome studies on opioids, including harms (e.g., refractory opioid dependence, … • Although evidence was limited, serious harms were not reported for either program. … • Systematic reviews of harms (regardless of indication) report that acetaminophen, prednisolone

108. Ankyloglossia Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/ankyloglossia_executive.pdf
     May 01, 2015 - , and Children Through Age 18 In order to identify all possible harms, we sought harms from all comparative … for harms, either reporting actual harms or specifically indicating that they found none. … Most studies that reported harms information explicitly noted that no significant harms were observed … (n = 17) or reported minimal harms. … Eighteen studies reported that no significant harms were observed.

109. CER 215 Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-215-depression-older-adults-comments.pdf
     March 28, 2019 - /doi.org/10.23970/AHRQEPCCER215 Source: https://effectivehealthcare.ahrq.gov/topics/depression-harms … Source: https://effectivehealthcare.ahrq.gov/topics/depression-harms/research Published Online: March … Data on harms of trazodone may still be relevant to clinicians but it is not likely to be used as a … because we lack comparative harms evidence. … In this report little data were available for specific harms.

110. Comparative Effectiveness Review No. 272_Genitourinary Syndrome of Menopause: A Systematic Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-272-genitourinary-syndrome-executive-summary.pdf
     July 01, 2024 - • Harms reporting was limited by sample sizes and short followup duration though most studies did … not find frequent serious harms. … to treatment, or the benefits or harms of endometrial surveillance for patients using hormonal therapies … examined the evidence for Key Questions related to GSM screening (KQ1), treatment effectiveness and harms … but serious harms, though most studies did not find evidence of frequent serious harms.

111. Kidney-Disease-Medicine Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/kidney-disease-medicine_executive.pdf
     January 01, 2012 - KQ4: Monitoring Harms KQ6: Treatment Harms Asymptomatic adults •With CKD risk factors •Without … Take into account potential screening harms. … increases harms. … Take into account potential monitoring harms. Key Question 4. … for worsening kidney function or damage increases harms.

112. Management of Insomnia Disorder | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/insomnia/research
     December 01, 2019 - Structured Abstract Objective To assess the efficacy, comparative effectiveness, and harms of treatments … measures that assess both sleep and daytime functioning associated with sleep), sleep parameters, and harms … Administration (FDA) labels warn about cognitive and behavioral changes, including driving impairment, and other harms … Observational studies suggest an association of hypnotics with infrequent but serious harms.

113. Otitis Media With Effusion: Comparative Effectiveness of Treatments | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/ear-infection/research
     March 01, 2021 - Structured Abstract Objectives To compare benefits and harms of strategies currently in use for managing … We compared benefits and harms among these treatments: tympanostomy tubes (TT), myringotomy (myr), adenoidectomy … Findings are reported for clinical and functional outcomes, and harms. … adenoid reduce OME and improve hearing in the short term, but both treatments also have associated harms

114. What is the most effective therapy for a depressed patient who has not responded to an SSRI? | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/get-involved/nominated-topics/what-is-the-most-effective-therapy-for-a-depressed-patient-who-has-not-responded-to-an-ssri
     November 01, 2017 - well the test, treatment, or intervention works   There is significant potential for side effects/harms … or diagnosis/identification for a particular disease, or risk assessment for a disease   Risks or harms … a condition or particular system of care   Delivery of a health service   Referral   Risks or harms … Harms: Are there risks, side effects, or harms you are concerned about? … specify what those are: There are potential harms

115. Comparative Effectiveness of Therapies for Children With Autism Spectrum Disorder | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/autism-update/clinician
     December 01, 2019 - Key Clinical Issue What evidence is available regarding the effectiveness, benefits, and harms of therapies … For many other interventions, the evidence is insufficient to permit an estimate of their benefits or harms … This does not mean that these interventions are not associated with benefits or harms but that further … [evidence insufficient] Harms Aripiprazole and risperidone are associated with significant weight … Whether there are any harms associated with behavioral, educational, allied health, or CAM interventions

116. App-F2-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/app-f2-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
     September 20, 2022 - Harms of tricyclic antidepressants versus placebo Author, Year Quality Pain Population Drug Class Drug … Harms of pregabalin versus placebo Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of pregabalin CR versus IR Author, Year Quality Pain Population Drug Class Drug Assessment Time … Harms of cannabis versus placebo Author, Year Quality Pain Population Drug Assessment Time (Wk) Time … Harms of lidocaine patch versus placebo Author, Year Quality Pain Population Drug Assessment Time (Wk

117. Hemorrhage-Postpartum Executive (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hemorrhage-postpartum_executive.pdf
     April 01, 2015 - Harms of Interventions for PPH Harms varied considerably across the 50 studies reporting harms data … Among the 50 studies reporting harms, we considered 11 as good quality for harms reporting and the … for harms reporting. … poor quality for harms reporting. … • Prespecifying harms, differentiating harms of interventions from sequelae of PPH wherever possible

118. Management of Postpartum Hemorrhage: Current State of the Evidence | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/hemorrhage-postpartum/clinician
     December 01, 2019 - is a summary of a systematic review evaluating the evidence regarding the potential benefits and harms … Harms of interventions are diverse and not well understood. … Table 3: Summary of Key Findings and Strength of Evidence for Harms of PPH Interventions Interventions … [evidence low] Evidence is insufficient to permit conclusions about the harms associated with the … [evidence low] Evidence is insufficient to permit conclusions about harms associated with other

119. Disposition of Comments for Comparative Effectiveness Review No. 240: Treatments for Acute Pain: A Systematic Review (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/cer-240-acute-pain-revised-comments.pdf
     December 29, 2020 - The report summarizes evidence on benefits as well as harms of NSAIDs. … The review summarized evidence on benefits as well as harms of NSAIDs. … Harms of opioids are well-described in the report. … Potential harms of opioids are described in the Background section. … This report focuses on benefits and harms of treatment for acute pain.

120. Local Hepatic Therapies for Metastases to the Liver From Unresectable Colorectal Cancer | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/colorectal-cancer-liver-metastases-therapies/research
     December 01, 2019 - Structured Abstract Objectives To characterize the comparative effectiveness and harms of various … Twenty-three articles addressed Key Questions (KQ) 1 (effectiveness) and 2 (harms) for patients ineligible … for systemic chemotherapy, and seven addressed KQ3 (effectiveness) and KQ4 (harms) for patients who … Evidence was insufficient to determine the comparative effectiveness or harms of these interventions. … Gaps in the research base, even for critical benefits or harms, are extensive, and the quality of studies